Literature DB >> 22007522

Pharmacokinetics of the combined preparation of lisinopril and hydrochlorothiazide on Chinese healthy volunteers.

Yang Wei1, Ying-Ying Sun, Ke-Shen Wang, Dan-Li Sun, Ming-You Zheng.   

Abstract

The aim of the present study, performed on two different groups of volunteers, is to characterize the pharmacokinetics of lisinopril/hydrochlorothiazide combined tablet. After administration of high, medium and low doses of lisinopril/hydrochlorothiazide combined tablets, AUC and C(max) of two compounds both increase significantly with increase of dose. Neither normalized AUC/Dose nor C(max)/Dose has significant difference between every two tested dose groups. The similar results can be observed as for the parameters of t(max). Lisinopril and hydrochlorothiazide are both eliminated with linear characteristics. After repeated administration of lisinopril/hydrochlorothiazide combined tablets, AUC, C(max) and C(min) of lisinopril in the steady state increase. AUC and C(min) increase significantly. As for hydrochlorothiazide, AUC, C(max), C(min), and t(max) also increase in steady state. AUC and C(min) increase significantly. Administered with the test medication, lisinopril has an fluctuation index (FI) value of 2.29 and reaches a relative steady concentration. But hydrochlorothiazide has an FI value of 4.09 with relatively large fluctuating concentrations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22007522

Source DB:  PubMed          Journal:  Yao Xue Xue Bao        ISSN: 0513-4870


  2 in total

1.  Fast and sensitive LC-MS/MS method for the simultaneous determination of lisinopril and hydrochlorothiazide in human plasma.

Authors:  Jaivik V Shah; Priyanka A Shah; Priya V Shah; Mallika Sanyal; Pranav S Shrivastav
Journal:  J Pharm Anal       Date:  2016-11-25

2.  Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation.

Authors:  Sarah Jane Commander; Huali Wu; Felix Boakye-Agyeman; Chiara Melloni; Chi Dang Hornik; Kanecia Zimmerman; Amira Al-Uzri; Susan R Mendley; Barrie Harper; Michael Cohen-Wolkowiez; Christoph P Hornik
Journal:  J Clin Pharmacol       Date:  2020-10-07       Impact factor: 2.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.